FLGR 242 is a specialized research compound evaluated in preclinical models for its targeted interaction with myostatin and transforming growth factor-beta (TGF-β) signaling cascades. This technical guide outlines the chemical characterization, receptor kinetics, reconstitution protocols, and analytical quality benchmarks for laboratory investigation of the flgr 242 peptide.
FLGR 242 is a specialized research compound evaluated in preclinical models for its targeted interaction with myostatin and transforming growth factor-beta (TGF-β) signaling cascades. This technical guide outlines the chemical characterization, receptor kinetics, reconstitution protocols, and analytical quality benchmarks for laboratory investigation of the flgr 242 peptide.
FLGR 242 is a synthetic peptide derivative designed specifically for in vitro assays and animal research models investigating negative regulators of muscle tissue development. Engineered to model specific binding domains observed in follistatin-like proteins, the flgr 242 peptide is primarily utilized by scientists to study signal transduction through Activin Type II receptors and associated Smad pathway activation. The compound is supplied strictly as a purified lyophilized powder for laboratory research use only.
In biomedical research, the flgr peptide serves as a valuable molecular tool for probing autocrine and paracrine regulatory circuits. By selective affinity targeting within the TGF-β superfamily, researchers utilize flgr-242 to observe cellular responses, gene expression alterations, and downstream protein synthesis pathways in controlled experimental environments without confounding physiological variables.
To ensure reproducible data across demanding cell culture and in vivo research protocols, PX1 Research subjects every lot of FLGR 242 to rigorous analytical characterization. Research facilities require uncompromised chemical purity to avoid off-target biological responses or toxic cellular artifacts caused by synthesis side-products or bacterial contaminants.
Each batch of FLGR 242 is manufactured in US-based GMP-compliant facilities and undergo comprehensive analytical verification before release. Every vial supplied by PX1 meets or exceeds the following laboratory standards:
- Chemical Purity: ≥98.0% verified by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). - Molecular Mass Verification: Confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS). - Endotoxin Quantification: Tested via Chromogenic LAL assay to guarantee <0.01 EU/μg for sensitive tissue culture and animal models. - Lot-Specific Documentation: Complete Certificate of Analysis (COA) issued by an independent ISO 17025 accredited testing laboratory. - Physical State: Sterile, lyophilized cake in sealed borosilicate glass vials with flip-off crimp caps. - Fulfillment & Distribution: Rapid same-day shipping on orders placed Monday through Friday, dispatched directly from domestic fulfillment hubs in California and Arizona.
Investigators can download lot-matched analytical certificates directly from our PX1 research hub or verify purity parameters prior to integrating compounds into active assay series.
The flgr-242 compound belongs to a class of engineered peptide sequences designed to mimic regulatory domains of endogenous binding proteins. Naturally occurring follistatin isoforms contain specialized cysteine-rich domains that establish high-affinity ionic and hydrophobic interactions with myostatin (Growth Differentiation Factor 8, or GDF-8) and related activin molecules.
In structural biology models, FLGR 242 isolates key functional sequence motifs to minimize non-specific binding while maintaining targeted receptor interaction profiles. ESI-MS analysis confirms a uniform molecular weight profile without truncated sequence fragments or incomplete deprotection adducts. The precise arrangement of amino acid residues in the flgr 242 peptide facilitates stable secondary conformation in neutral aqueous buffers, enabling precise binding kinetic measurements in surface plasmon resonance (SPR) and enzyme-linked immunosorbent assays (ELISA).
Preclinical studies suggest that the biological activity of FLGR 242 centers on its capacity to sequester extracellular growth factors before they interact with transmembrane receptor complexes. Under physiological conditions, myostatin binds to Activin Receptor Type IIB (ActRIIB), triggering the recruitment and phosphorylation of Alk4/Alk5 coreceptors. This event initiates intracellular Smad2 and Smad3 phosphorylation, which subsequently downregulates the Akt/mTOR signaling axis responsible for translational protein synthesis.
In vitro data indicate that introduction of the flgr peptide into cell culture media disrupts this cascade by competitively binding extracellular GDF-8 molecules. By neutralizing soluble myostatin ligands, FLGR 242 attenuates downstream Smad2/3 nuclear translocation in C2C12 myoblast lines and primary satellite cell cultures. Researchers frequently evaluate research peptides targeting this system to map changes in gene transcription, specifically tracking markers such as MyoD, myogenin, and atrogin-1.
Additionally, rodent models investigating systemic administration of myostatin antagonist peptides suggest altered skeletal muscle protein turnover rates, enabling the measurement of cross-sectional fiber area changes, capillary density, and satellite cell activation parameters.
When designing protocols to investigate muscle regulatory pathways, researchers frequently evaluate multiple antagonist modalities. FLGR 242 occupies a distinct niche within the class of TGF-β binding agents alongside full-length proteins and soluble receptor constructs.
A comparison of key myostatin-modulating research compounds highlights differing operational characteristics:
- follistatin-315: A full-length endogenous protein isoform possessing broader activin-binding capability and tissue-retention characteristics, often studied for systemic vs. localized tissue binding.
- ace-031: A soluble fusion protein consisting of the extracellular domain of ActRIIB linked to the Fc portion of IgG, designed as a decoy receptor for myostatin and activins.
- igf-1-lr3: A synthetic analog of insulin-like growth factor 1 operating through the receptor tyrosine kinase / Akt pathway, representing a complementary, non-myostatin-dependent hypertrophic signaling cascade.
- FLGR 242: A sequence-optimized peptide fragment engineered to retain high affinity for myostatin while offering lower molecular weight, superior batch-to-batch synthetic consistency, and reduced non-specific activin neutralization in target assays.
Evaluating these compounds in parallel allows laboratory investigators to dissect specific contributions of receptor decoy inhibition versus direct ligand sequestration across varied experimental models.
Application of the flgr 242 peptide spans several core areas of basic science and translational preclinical research. In muscle cell culture, C2C12 myoblasts treated with recombinant myostatin normally exhibit impaired differentiation and reduced myotube fusion diameters. Co-incubation assays incorporating FLGR 242 demonstrate a dose-dependent rescue of myotube formation, establishing its efficacy as a control compound in TGF-β pathway inhibition assays.
In rodent models of muscle atrophy—such as hindlimb unloading, dexamethasone exposure, or denervation models—investigators utilize FLGR 242 to measure attenuation of muscle mass loss and functional force generation characteristics. Because FLGR 242 is synthesized via solid-phase peptide synthesis (SPPS) rather than recombinant cell expression, it eliminates variable post-translational glycosylation patterns, providing high reproducibility across long-term animal studies.
Researchers exploring metabolic regulation also deploy FLGR 242 to evaluate secondary effects on adipose tissue distribution and glucose homeostasis, as myostatin signaling cross-talks extensively with systemic energy expenditure and insulin sensitivity pathways. Additional complementary peptides such as peg-mgf and bpc-157 are frequently included in multi-arm tissue regeneration studies.
FLGR 242 is supplied as a lyophilized (freeze-dried) powder containing 15mg of highly purified peptide substance per vial. Proper reconstitution procedures are required to maintain peptide integrity and prevent aggregation prior to assay administration.
1. Reconstitution Medium: Lyophilized FLGR 242 should be reconstituted using sterile bacteriostatic water (containing 0.9% benzyl alcohol) for multi-use laboratory procedures, or sterile 0.9% sodium chloride / phosphate-buffered saline (PBS) for immediate single-use in vitro cell culture assays where preservatives may affect cell viability. 2. Reconstitution Technique: Allow the vial to equilibrate to room temperature before reconstitution. Direct the diluent stream against the glass wall of the vial rather than directly onto the lyophilized cake. Gently swirl or invert the vial until the peptide dissolves completely. Do not vortex or agitate vigorously, as mechanical shear stress can disrupt peptide tertiary structure or cause foaming. 3. Concentration Calibration: Adding 1.5 mL of diluent to a 15mg vial yields a stock concentration of 10 mg/mL, simplifying serial dilution calculations for microplate reader assays and micromanipulation systems.
Lyophilized FLGR 242 exhibits excellent chemical stability when stored under controlled laboratory environmental conditions. Unopened vials stored at -20°C or -80°C remain stable for up to 24 months from the date of manufacture. Protect lyophilized vials from direct light exposure.
Once reconstituted into aqueous solution, the flgr 242 peptide must be handled under cold-chain conditions. Reconstituted solutions in bacteriostatic water remain stable for up to 28 days when maintained at 2°C to 8°C. For long-term storage of reconstituted peptide, aliquot the solution into single-use sterile polypropylene tubes and store at -80°C to eliminate repeated freeze-thaw cycles, which induce mechanical peptide degradation.
Detailed storage handling matrix for laboratory staff:
- Lyophilized (Unopened, -20°C to -80°C): Up to 24 Months - Lyophilized (Unopened, 2°C to 8°C): Up to 90 Days - Reconstituted in Bacteriostatic Water (2°C to 8°C): 28 Days - Reconstituted Aliquots (-80°C): Up to 6 Months (Avoid Freeze-Thaw)
Acquiring reliable, high-purity materials is critical for university laboratories, contract research organizations (CROs), and private biotechnology research entities. Fluctuations in raw peptide purity can compromise experimental statistical power and introduce unexplained assay variance.
PX1 Research maintains a fully integrated supply chain with domestic production, enabling institutional buyers to establish reliable supply schedules. Laboratories requiring high-volume quantities or custom lot sizes of FLGR 242 can access tailored institutional terms through our wholesale lab accounts portal. All bulk orders carry identical strict verification standards, including single-lot HPLC traces, mass spectra, and endotoxin certificates provided prior to dispatch.
What is flgr 242?
FLGR 242 is a synthetic research peptide derived from follistatin structural motifs. It is designed for laboratory investigation into the inhibition of myostatin (GDF-8) and related TGF-β superfamily signaling pathways in muscle tissue models.
What is the primary function of the flgr 242 peptide in laboratory research?
The flgr 242 peptide is studied for its ability to bind extracellular myostatin ligands, blocking their interaction with Activin Type II receptors (ActRIIB) and preventing downstream Smad2/3 signaling in cell cultures and animal models.
How is flgr peptide purity verified at PX1 Research?
Every lot of flgr peptide undergoes rigorous testing via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify ≥98% purity, along with Electrospray Ionization Mass Spectrometry (ESI-MS) for identity and LAL chromogenic assays for endotoxin quantification.
What is the difference between flgr-242 and standard Follistatin 315?
While Follistatin 315 is a full-length endogenous protein with multiple binding domains, flgr-242 is a synthesized, truncated sequence designed specifically for targeted myostatin binding with reduced sequence complexity and higher synthetic batch consistency.
What diluent should be used to reconstitute FLGR 242 15mg?
For multi-use laboratory research, sterile bacteriostatic water containing 0.9% benzyl alcohol is recommended. For sensitive in vitro cell culture applications where preservatives may interfere with cellular viability, sterile phosphate-buffered saline (PBS) or sterile water for injection should be utilized.
How should reconstituted FLGR 242 be stored in the lab?
Reconstituted FLGR 242 solution should be stored at 2°C to 8°C for up to 28 days if prepared with bacteriostatic water. For long-term storage, aliquot the solution into sterile tubes and store at -80°C to avoid damaging freeze-thaw cycles.
What are the endotoxin limits for PX1 Research FLGR 242?
PX1 Research guarantees endotoxin levels below 0.01 EU/μg for FLGR 242, ensuring suitability for delicate primary cell cultures and in vivo animal research models.
Where does PX1 Research ship FLGR 242 orders from?
All orders are fulfilled directly from domestic facilities located in California and Arizona, with same-day shipping available for orders completed Monday through Friday before cut-off times.
Can I obtain a Certificate of Analysis (COA) for my lot of FLGR 242?
Yes. Every shipment includes lot-matched access to full third-party Certificate of Analysis documentation, including HPLC chromatograms and mass spectrometry reports issued by ISO 17025 accredited analytical laboratories.
Is FLGR 242 approved for human consumption or therapeutic use?
No. FLGR 242 is strictly supplied as a research chemical for in vitro laboratory experiments and preclinical animal research. It is not approved for human consumption, clinical use, or veterinary therapeutic applications.
Are bulk institutional purchasing options available for FLGR 242?
Yes, university laboratories, biotechnology entities, and research institutions can request bulk pricing and custom supply arrangements through the PX1 Research wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.